Purchase Order 75N91021P00393
Award Date
5/1/21
Potential Completion Date
4/30/22
Potential Value
$83K
Federal Agency
National Cancer Institute
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed price purchase order contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services (HHS), to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The $235,228 contract provides for preventive maintenance, emergency service, and support for a government-owned Illumina NextSeq 2000 sequencing system used in support of the NCI's research...
This firm fixed-price purchase order contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for maintenance services on a government-owned Illumina NovaSeq 6000 sequencing instrument. The $134,247.36 contract provides annual preventive maintenance, emergency repair, software/firmware updates, replacement parts, and technical support for the sequencing system located at the NCI's Laboratory of Pathology in Bethesda,...
This firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Illumina, Inc., a manufacturer of genetic sequencing systems and solutions, for preventive maintenance, emergency service, and support for a government-owned Illumina NovaSeq 6000 Sequencing System. The contract has a period of performance from August 1, 2022 to July 31, 2023 and a potential value of $119,523.28. The requirement was...
The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a $130,847 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The purpose is to procure preventive maintenance services for a government-owned Illumina NovaSeq 6000 Sequencing System located at the National Cancer Institute in Bethesda, Maryland. The Laboratory of Pathology requires these services to maintain optimal instrument operation, generate comparable...
This is a $142,990 firm fixed price purchase order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of genomic sequencing systems and analytical instruments. The contract has no set-aside designation. Illumina has previously received prime federal contract awards from other agencies like the CDC, USDA, and VA to provide sequencing systems, reagents, and related services in support of genomics...
This is a firm fixed price purchase order awarded by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis equipment. The contract provides for an equipment maintenance agreement on Illumina sequencing systems, such as NextSeq, NovaSeq, MiSeq, and iSeq models, with a ceiling value of $16,198.00 and a performance period ending on December 4, 2025. The contract does...
This is a $145,853.00 firm fixed price purchase order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Illumina, Inc. The contract is for a maintenance agreement for scientific equipment, specifically Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems and related reagents and consumables. Illumina is a for-profit manufacturer that has provided a range of genomic sequencing and analysis products and services...
This firm fixed-price purchase order was awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), to Illumina, Inc. for the procurement of one (1) Illumina NextSeq 550 DX Sequencing System. The $281,764 contract supports the NCI's Comprehensive Oncologic Molecular Pathology and Sequencing Service (COMPASS) and has an ultimate completion date of September 6, 2024. The system must be capable of sequencing DNA libraries using in vitro diagnostic...
This is a $202,000.00 firm fixed price purchase order awarded by the National Cancer Institute (NCI), a civilian agency within the National Institutes of Health (NIH), to Illumina, Inc. for the provision of an Illumina NextSeq 500 sequencing system. The contract has no set-aside designation. Through past contract awards, Illumina has provided a range of genomic sequencing instruments, reagents, and support services to various federal agencies including the NIH, Centers for Disease Control and...
This firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute (NCI) to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The contract provides for preventive and emergency maintenance of government-owned Illumina instrumentation, including MiSeq, cBOT, Freedom EVO, and NextSeq 500 systems, utilized for genome analysis in support of NCI's cancer research....